Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.03 Analyst target: $12.80 Upside: 322.44%
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
See the full interactive analysis & chart →Informational only — not investment advice.